X‑Chem and Gilead Announce Drug Discovery Collaboration
WALTHAM, Mass. – November 28, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Gilead Sciences, Inc. (Gilead). Under the terms of the agreement, XChem will screen its proprietary DEXTM libraries, which contain >120 billion individually DNA-encoded small molecules, toward the discovery of novel, high-value therapeutic leads against targets in antiviral and additional therapeutic areas. Gilead has the option to license drug leads discovered under the collaboration, and will be responsible for further development and commercialization of the resulting programs.
X‑Chem’s DNA-Encoded Library (DEL) Platform Enables the Discovery of Lead-Like Molecules for Medicinal Chemistry Progression
Discovery of Novel, Potent Inhibitors of Hydroxy Acid Oxidase 1 (HAO1) Using DNA-Encoded Chemical Library Screening X-Chem’s DNA-encoded library (DEL)...
Medicinal Chemistry
English French Delivering Feasible Candidates With Decades of Experience and a Proven Track Record of Client Success With a leadership...
Software and Science Go Hand in Hand at X‑Chem: Informatics Tools for a Scalable and Effective DEL Platform
From the very beginnings of X-Chem, we recognized the need to invest in software capabilities. DNA-encoded library (DEL) technology generates...